Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 198-201

  Mhawech Fauceglia, Paulette ^a   Wang, Dan ^b   Samrao, Damanzoopinder ^a   Godoy, Heidi ^c   Ough, Faith ^a   Liu, Song ^b   Pejovic, Tanja ^d   Lele, Shashikant ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Biostatistics ^*  (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Disease outcome; Immunoexpression; Ovarian serous cancer; PAX8

Indexed keywords

TRANSCRIPTION FACTOR PAX8;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865699113     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.06.012     Document Type: Article

References (18)

1. The National Cancer Institute's Surveillance, Epidemiology and End Results Program < http://seer.cancer.gov/ >. The Center for Disease Control and Prevention's National Program of Cancer Registries Web site < http://www.cdc.gov/cancer/npcr/uscs/index.htm >; 2012.
2. N. Colombo, T. Van Gorp, G. Parma, F. Amant, G. Gatta, and C. Sessa Ovarian cancer. Crit Rev Oncol Hematol 60 2006 159 179
3. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2007 3621 3627
4. I. Skirnisdòtir, and B. Sorbe Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIG0-stages III-IV) epithelial ovarian carcinoma Int J Oncol 30 2007 727 734
5. P. Wimbeger, N. Lehmann, R. Kimmig, A. Burges, W. Meier, and A. Du Bois Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An explatory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group (AGO-AVAR) Gynecol Oncol 106 2007 69 74
6. J. Mittag, E. Winterhager, K. Bauer, and R. Grummer Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacment therapy Endocrinology 148 2007 719 725
7. M. Bouchard Transcriptional control of kidney development. Differentiation 72 2004 295 306
8. H.W. Cheung, G.S. Cowley, B.A. Weir, J.S. Boehm, S. Rusin, and J.A. Scott Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer Proc Natl Acad Sci U S A 108 2011 12372 12377
9. N.J. Bowen, S. Logani, E.B. Dickerson, L.B. Kapa, M. Akhtar, and B.B. Benigno Emerging roles for PAX8 in ovarian cancer and endosalpingeal development Gynecol Oncol 104 2007 331 337
10. A.R. Laury, J.L. Hornick, R. Perets, J.F. Krane, J. Corson, and R. Drapkin PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma Am J Surg Pathol 34 2010 627 635
11. A.R. Laury, R. Peters, H. Piao, J.F. Krane, J.A. Barletta, and C. French A comprehensive analysis of PAX8 expression in human epithelial tumors Am J Surg Pathol 35 2011 816 826
12. D. Nonaka, L. Chiriboga, and R.A. Soslow Expression of Pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas Am J Surg Pathol 32 2008 1566 1571
13. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
14. W.T. Creasman Announcements: FIGO stages: 1988 revision Gynecol Oncol 35 1989 125 127
15. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, and D.M. Gershenson Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
16. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Bärlund, P. Schraml, and S. Leighton Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 1998 844 847
17. P. Mhawech-Fauceglia, D. Wang, T. Menesses, U. Chandavarkar, F. Ough, and Y. Lin PAX8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens Histopathology 60 2012 1019 1020
18. M. Kobel, S.E. Kalloger, N. Boyd, S. McKinney, E. Mehl, and C. Palmer Ovarian carcinoma subtypes are different diseases: implications for biomarker studies Plos one 12 2008 e232